Related Experiment Video
Updated: Dec 21, 2025

Author Spotlight: Genetically Engineered Mouse Models and Pathological Characterization of Neurofibromatosis Type 1 Associated Tumors
Published on: May 17, 2024
Dedifferentiated Chordoma: Clinicopathologic and Molecular Characteristics With Integrative Analysis
Yin P Hung1, Julio A Diaz-Perez2, Gregory M Cote3
1Departments of Pathology.
Abstract:
Dedifferentiated chordoma is a rare chordoma subtype characterized by a high-grade sarcoma juxtaposed to conventional chordoma. We identified a series of dedifferentiated chordomas, reviewed clinicopathologic features, performed next-generation sequencing in select cases, and analyzed all related English-language publications. Our series included 7 men and 3 women (age 15 to 80 y [median: 54 y]; <1% of >1000 chordomas surveyed). The tumor (2.8 to 24.5 cm [median: 5.8 cm] in size) presented de novo or as recurrence (including postradiotherapy) in sacrum (n=5), skull base (n=2), lumbar spine (n=1), thoracic/mediastinum (n=1), and lung (n=1; as metastasis). Histologically, the dedifferentiated component (3% to 95% [median: 60%]) was pleomorphic-to-fibrosarcomatous, juxtaposed to conventional (n=8) or chondroid (n=2) component. By immunohistochemistry, the conventional/chondroid component consistently expressed cytokeratin and brachyury, whereas the dedifferentiated component showed loss of both. We identified a sacral conventional chordoma with INI1 loss, with one of the lung metastases showing biphasic histology with loss of cytokeratin and brachyury in the dedifferentiated component. Sequencing identified tumor suppressor mutations in 4 tumors, including TP53 mutations in the dedifferentiated component in 3 tumors. Of 7 patients with follow-up, 6 developed metastases; 4 died at 15 to 99 months (median: 24 mo) after dedifferentiated chordoma diagnosis. Collectively, of 87 dedifferentiated chordoma patients described in 1913-2020 (including 10 herein), the median overall survival was 20 months. In summary, dedifferentiated chordoma involves diverse sites and presents de novo, postradiotherapy, or as recurrence/metastasis months-to-years after initial diagnosis. The dedifferentiated component shows loss of brachyury and cytokeratin staining and harbors recurrent TP53 mutations, implicating tumor suppressor dysregulation in chordoma dedifferentiation.
Insights
Dedifferentiated chordoma, a rare subtype, features high-grade sarcoma alongside conventional chordoma. Genetic analysis reveals TP53 mutations in the dedifferentiated component, impacting tumor suppressor pathways and prognosis.
Area of Science:
- Oncology
- Pathology
- Genetics
Background:
- Dedifferentiated chordoma is a rare, aggressive subtype of chordoma.
- It is characterized by the presence of a high-grade sarcoma component adjacent to conventional chordoma.
- Understanding its clinicopathologic and molecular features is crucial for diagnosis and treatment.
Purpose of the Study:
- To characterize the clinicopathologic features of dedifferentiated chordoma.
- To investigate the molecular alterations, including genetic mutations, in dedifferentiated chordoma.
- To analyze patient outcomes and survival data for this rare tumor subtype.
Main Methods:
- Retrospective review of a series of dedifferentiated chordoma cases.
- Histopathological and immunohistochemical analysis (cytokeratin, brachyury, INI1).
- Next-generation sequencing (NGS) for genetic mutation profiling.
- Comprehensive literature review of previously reported cases.
Main Results:
- Dedifferentiated chordoma occurs in diverse anatomical sites (sacrum, skull base, spine, mediastinum, lung metastasis).
- The dedifferentiated component shows loss of cytokeratin and brachyury expression.
- Next-generation sequencing identified tumor suppressor mutations, notably TP53 mutations in 3/4 analyzed cases.
- High rates of metastasis and mortality were observed, with a median overall survival of 20 months.
Conclusions:
- Dedifferentiated chordoma presents de novo, as recurrence, or metastasis, often years after initial diagnosis.
- Loss of brachyury and cytokeratin, along with TP53 mutations, are key features of the dedifferentiated component.
- Tumor suppressor dysregulation likely plays a significant role in chordoma dedifferentiation and aggressive behavior.
More Related Videos
11:28Isolation and Characterization of a Head and Neck Squamous Cell Carcinoma Subpopulation Having Stem Cell Characteristics
Published on: May 11, 2016
09:17Digital Spatial Profiling for Characterization of the Microenvironment in Adult-Type Diffusely Infiltrating Glioma
Published on: September 13, 2022